Phio Pharmaceuticals Corp.
Close on Oct 19, 2026
- Market cap
- $10.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-0.36 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-0.34 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.44 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | $-0.41 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-1.54 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | $-3.62 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 2, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | $-1.14 | – |
Press releases
Announcements Phio Pharmaceuticals filed with the SEC
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Other events · EX-99 to Form 8-K
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Phio Announces Safety Monitoring Committee ’ s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Exercise of Warrants
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Positive Pathology Results:
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 3, 2025
Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Exercise of Warrants
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED JUNE 25, 2025
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 7, 2025
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL ® PH-762 Skin Cancer Study
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports 2024 Year End Financial
Results of operations · EX-99.1 to Form 8-K
Announces Appointment of David H. Deming to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY THE COMPANY ON JANUARY 16, 2025
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Promising Results of Second Cohort from its Ongoing Clinical Study of PH-762
Other events · EX-99.1 to Form 8-K
Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Positive Safety Monitoring Committee (SMC) Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Upcoming Presentation at the 39 th
Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Phio Pharmaceuticals Announces Exercise of
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Phio Pharmaceuticals Terminates Share Purchase
Agreement terminated · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY THE COMPANY ON JULY 2, 2024
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead
Other events · EX-99.1 to Form 8-K